As the follow-on to mine below — on the markets laughing off Trump’s Sharpie scribbles — on pharmaceuticals pricing… I’ll set out the first in the series of pharma majors’ lobby spend in the first quarter of 2025.

Do enjoy — this will be one of five or seven in a series, depending on how ambitious I feel this week. [And whether the Qatari “trojan horse” deal gets done. Hah.]

…H.R. 1244, Reducing Drug Prices for Seniors Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025; S. 1040, Drug Competition Enhancement Act; S. 1339, Pharmacy Benefit Manager Reform Act; S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021….

Issues relating to [US House]: 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2025 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues….

H.R. 1244, Reducing Drug Prices for Seniors Act; Issues relating to [Senate]: Medicare; Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; FY-2025 Budget and Appropriations Legislation; Medicaid drug rebate program (MDRP)….

Issues relating to [House & Senate]: Tax reform and tax policy, generally; Tax Cuts and Jobs Act of 2017 (P.L. 115-97); Inflation Reduction Act (P.L. 117-169), provisions relating to budget reconciliation and taxes….

H.R. 8467, Farm, Food, and National Security Act of 2024; Issues relating to: United Stated Department of Agriculture; Animal and Plant Health Inspection Service; Final Rule regarding use of electronic identification eartags as official identification in cattle and bison (89 Fed. Reg. 39,541 — 39,566, May 9, 2024)….

Now you know. But this will now prove out… that Tangerine’s silly Sharpie is no match for world class lobbying efforts. They’ve already (long ago) won the match — in the House and Senate. Out.

नमस्ते